المؤلفون: V. Breder V., D. Abdurakhmanov T., V. Petkau V., P. Balakhnin V., M. Volkonsky V., K. Grechukhina S., M. Zafirova A., I. Mikerov A., I. Pokataev A., A. Khasanova I., В. Бредер В., Д. Абдурахманов Т., В. Петкау В., П. Балахнин В., М. Волконский В., К. Гречухина С., М. Зафирова А., И. Микеров А., И. Покатаев А., А. Хасанова И.

المصدر: Malignant tumours; Том 11, № 3 (2021); 45-52 ; Злокачественные опухоли; Том 11, № 3 (2021); 45-52 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: hepatocellular carcinoma, HCC, lenvatinib, real‑world clinical practice, гепатоцеллюлярный рак, ГЦР, гепатоцеллюлярная карцинома, ГЦК, ленватиниб, реальная клиническая практика

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/919/665; American Cancer Society. Cancer facts & figures 2020. (2020). Электронный ресурс. Режим доступа: https://www.cancer. org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf.; Yang, Ju Dong, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature reviews Gastroenterology & Hepatology. 2019; 16 (10): 589-604.; Singal A. G. et al. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncology. 2021. 17 (21) https://doi.org/10.2217/fon-2021-0242.; Омельяновский В. В., Максимкина Е. А., Ивахненко О. И., Авксентьева М. В., Сура М. В., Хачатрян Г. Р. Соверше нствование системы формирования перечней лекарственных препаратов для медицинского применения: анализ изменений Постановления Правительства РФ №871. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13 (2):113-123. https://doi.org/10.17749/2070-4909/farmakoekonomika. 2020.032.; Журавлева Н. И., Шубина Л. С., Сухоруких О. A. Обзор методик оценки достоверности научных доказательств и убедительности рекомендаций, применяемых при разработке клинических рекомендаций в Российской Федерации. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019;12 (1):34-41. https://doi. org/10.17749/2070-4909.2019.12.1.34-41.; Блинов Д. В., Акарачкова Е. С., Орлова А. С., Крюков Е. В., Корабельников Д. И. Новая концепция разработки к линических рекомендаций в России. ФАРМ АКОЭКОНОМИК А. Современна я фармакоэкономика и фармакоэпидемиология. 2019;12 (2):125-144. https://doi.org/10.17749/2070-4909.2019.12.2.125-144.; Камилова Д. П., Овчинникова М. М., Абляева Э. Ш., Левиашвили М. М., Стулева Н. С., Бройтман Е. В., Ганихина М. А., Маясина Е. Н., Исхакова Л. Ф., Боярский К. Ю., Овсянникова Е. Н., Барахоева З. Б., Никитин С. В., Бендусов И. А., Фетисова Ю. А., Юдина М. А., Тарарашкина Е. С., Хетагурова Д. Т., Блинов Д. В., Ползиков М. А. Эффективность применения биоаналогового фоллитропина альфа в реальной клинической практике: результаты наблюдательного исследования «ФОЛЛИТРОПИН». Акушерство, Гинекология и Репродукция. 2021;15 (1):5-21. https://doi.org/10.17749/2313-7347/ob. gyn. rep. 2021.212.; Бузуверова О. О., Федяева В. К., Сухоруких О. А. Методологические и практические аспекты применения метода RAND/UCLA для разработки клинических рекомендаций и критериев оценки качества медицинской помощи. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019;12 (4):327-332. https://doi. org/10.17749/2070-4909.2019.12.4.327-332.; Омельяновский В. В., Федяева В. К., Мусина Н. З. Концепция многокритериального анализа принятия решений в текущей системе оценки технологий в здравоохранении России. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2018;11 (3):3-7. https://doi.org/10.17749/2070-4909.2018.11.3-003-007.; Finn R. S. et al. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT] //Annals of Oncology. – 2018. – Т. 29. – С. viii17-viii18.; Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 2018 Mar;7 (1):1-19. doi:10.1159/000487148. PMID: 29662829; PMCID: PMC5892376.; Briggs A. et al. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treat-ment of unresectable hepatocellular carcinoma //British journal of cancer. – 2020. – Т. 122. – №. 12. – С. 1754-1759.; Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015 Feb 20;33 (6):550-8. doi:10.1200/JCO. 2014.57.9151. Epub 2014 Dec 15. PMID: 25512453; PMCID: PMC4322258.; Vogel A., Frenette C., Sung M., Daniele B., Baron A., Chan S. L., Blanc J. F., Tamai T., Ren M., Lim H. J., Palmer D. H., Takami Y., Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2021. doi:10.1159/000516490.; Alsina et al. Subsequent anticancer medication: a post hoc analysis from REFLECT; Liver Cancer 2020; 9:93–104; DOI:10.1159/000504624.; Huynh J, Cho MT, Jae-Hoon Kim E, et al. Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). Journal of Clinical Oncology. 39, no. 3_suppl (January 20, 2021) 298-298. DOI:10.1200/JCO. 2021.39.3_suppl. 298.; Sho T. et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria //Hepatology Research. – 2020. – Т. 50. – №. 8. – С. 966-977.; Caraceni P, Riggio O, Angeli P, et al. Long-Term albumin administration in decompensated cirrhosis (answer): an open-label randomised trial. Lancet 2018;391:2417–29. HYPERLINK “http://dx.doi.org/10.1016/S0140-6736 (18)30840-7”doi:10.1016/S0140-6736 (18)30840-7.; Dang H, Yeo YH, Yasuda S, et al. Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. Hepatology 2020;71:1910-22.; Koroki, K., Kanogawa, N., Maruta, S., Ogasawara, S., Iino, Y., Obu, M., Okubo, T., Itokawa, N., Maeda, T., Inoue, M. and Haga, Y., Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2021; pp. 1-12. https://doi. org/10.1159/000515552.; Kudo M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carci-noma: a randomised phase 3 non-inferiority trial //The Lancet. – 2018. – Т. 391. – №. 10126. – С. 1163-1173.; Finn R. S. et al. IMbrave150 Investigators et al //Atezolizumab plus bevacizumab in unresectable hepatocellular car-cinoma. N. Engl. J. Med. – 2020. – Т. 382. – №. 20. – С. 1894-1905.; Cabibbo G., Celsa C., Enea M., Battaglia S., Rizzo G. E., Grimaudo S., Matranga D., Attanasio M., Bruzzi P., Craxì A., Cammà C. Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis. Cancers. 2020; 12 (8): 21-32.; European Association For The Study Of The Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology 69.1 (2018): 182-236.; Бредер В. В., Косырев В. Ю., Кудашкин Н. Е., Лактионов К. К. Гепатоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема. Медицинский совет. 2016;10: 10-18.; Бредер В. В., Балахнин П. В., Виршке Э. Р., Косырев В. Ю., Ледин Е. В., Петкау В. В. Практические рекомендации по лекарственному лечению больных гепатоцеллюлярным раком. DOI:10.18027/2224-5057-2020-10-3s2-25RUSS-CO, 2020.; Клинические рекомендации Рак печени (гепатоцеллюлярный) 2020. МЗ РФ. Интернет ресурс: http://cr. ros-minzdrav. ru/#!/schema/709 Дата обращения: 16.05.2020.; Kudo M. et. al., Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study Cancers 2019, 11, 1084.; Llovet J. M. et al. Molecular therapies and precision medicine for hepatocellular carcinoma //Nature reviews Clinical oncology. – 2018. – Т. 15. – №. 10. – С. 599-616.; Breder V. V. et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. Journal of Clinical Oncology 2021 39:15_suppl, 4073-4073.; https://www.malignanttumors.org/jour/article/view/919

الاتاحة: https://www.malignanttumors.org/jour/article/view/919
https://doi.org/10.18027/2224-5057-2021-11-3-45-52

المؤلفون: E. Antonova Yu., E. Moroz A., D. Podluzhny V., N. Kudashkin E., I. Dzhanyan A., A. Volkov Yu., K. Laktionov K., V. Breder V., Е. Антонова Ю., Е. Мороз А., Д. Подлужный В., Н. Кудашкин Е., И. Джанян А., А. Волков Ю., К. Лактионов К., В. Бредер В.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 94-100 ; Медицинский Совет; № 20 (2021); 94-100 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: fibrolamellar carcinoma, liver tumor, prognosis, sclerosing component, microvascular invasion, фиброламеллярная карцинома, опухоль печени, прогноз, склерозирующий компонент, микрососудистая инвазия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6585/5968; Craig J.R., Peters R.L., Edmondson H.A., Omata M. Fibrolamel – lar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer. 1980;46(2):372–379. https://doi.org/10.1002/1097-0142(19800715)46:2 3.0.co;2-s.; Edmonson H.A. Differential diagnosis of tumors and tumor – like lesion of liver in infancy and childhood. AMA Am Arch Dis Child. 1956;91(2): 168–186. https://doi.org/10.1001/archpedi.1956.02060020170015.; Berman M.M., Libbey P., Foster J.H. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. 1980;46(6):1148–1155. https://doi.org/10.1002/1097-0142(19800915)46:63.0.co;2-j.; Lau W.Y. Primary hepatocellular carcinoma. In: Blumgart L.H., Fong Y. (eds.). Surgery of the Liver and Biliary Tract. 3rd ed. London: W.B. Saunders; 2000, pp. 1423–1450.; Choti M.A., Espat N.J., Talavera F., Balducci L., Nathan H. Fibrolamellar carcinoma. eMedicine. 2020. Available at: http://emedicine.medscape.com/article/278354-overview.; Epstein B.E., Pajak T.F., Haulk T.L., Herpst J.M., Order S.E., Abrams R.A. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. 1999;22(1):22–28. https://doi.org/10.1097/00000421-199902000-00006.; Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17(4):401–405. https://doi.org/10.1046/j.1440-1746.2002.02734.x.; Pinna A.D., Iwatsuki S., Lee R.G., Todo S., Madariaga J.R., Marsh J.W. et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy of transplantation. Hepatology. 1997;26(4):877–883. https://doi.org/10.1002/hep.510260412.; Ringe B., Wittekind C., Weimann A., Tusch G., Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175(4):299–305. Available at: https://pubmed.ncbi.nlm.nih.gov/1329242.; El-Gazzaz G., Wong W., El-Hadary M.K., Gunson B.K., Mirza D.F., Mayer A.D. et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(1 Suppl.):S406–S409. Available at: https://pubmed.ncbi.nlm.nih.gov/11112043.; Moreno-Luna L.E., Arrieta O., García-Leiva J., Мartínez В., Torre А., Uribe М., León-Rodríguez E. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005;5:142. https://doi.org/10.1186/1471-2407-5-142.; Stipa F., Yoon S.S., Liau K.H., Fong Y., Jarnagin W.R., D’Angelica M. et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331–1338. https://doi.org/10.1002/cncr.21703.; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. С. 14–71. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.; Kakar S., Burgart L.J., Batts K.P., Garcia J., Jain D., Ferrell L.D. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18(11):1417–1423. https://doi.org/10.1038/modpathol.3800449.; Pérez-Guillermo M., Masgrau N.A., García-Solano J., Sola-Pérez J., de Agustín y de Agustín P. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. 1999;21(3):180–187. https://doi.org/10.1002/(sici)1097-0339(199909)21:3 3.0.co;2-o.; Allen D.C., Cameron R.I. (eds.). Histopatology Speciments: Clinical, Pathological and Laboratory Aspects. 2nd ed. London: Springer-Verlag; 2013, pp. 99–110. http://doi.org/10.1007/978-0-85729-673-3.; Chrisinger J.S.A., Al-Zaid T., Keung E.Z., Leung C., Lin H.Y., Roland C.L. et al. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019;120(3):382–388. https://doi.org/10.1002/jso.25585.; Волков А.Ю., Козлов Н.А., Неред С.Н., Стилиди И.С., Строганова А.М., Архири П.П. и др. Инвазивные свойства забрюшинных высокодифференцированных липосарком в зависимости от доли склерозирующего компонента в опухоли. Российский онкологический журнал. 2020;25(2):14–23. https://doi.org/10.17816/1028-9984-2020-25-2-50-55; Волков А.Ю., Козлов Н.А., Неред С.Н., Стилиди И.С., Строганова А.М., Архири П.П. и др. Прогностическое значение миксоидного матрикса в забрюшинной высокодифференцированной липосаркоме. Сибирский онкологический журнал. 2021;20(1):46–52. https://doi.org/10.21294/1814-4861-2021-20-1-46-52.; https://www.med-sovet.pro/jour/article/view/6585

الاتاحة: https://www.med-sovet.pro/jour/article/view/6585
https://doi.org/10.21518/2079-701X-2021-20-94-100

المؤلفون: I. Dzhanyan A., V. Breder V., O. Borisova I., K. Laktionov K., И. Джанян А., В. Бредер В., О. Борисова И., К. Лактионов К.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 150-154 ; Медицинский Совет; № 20 (2021); 150-154 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: hepatocellular carcinoma, second line, checkpoint inhibitors, pembrolizumab, sorafenib, гепатоцеллюлярный рак, вторая линия, ингибиторы контрольных точек, пембролизумаб, иммунотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6593/5976; Казанцева М.А., Бредер В.В., Лактионов К.К. Иммунотерапия гепатоцеллюлярного рака: начало и перспективы. Медицинский совет. 2019;(10):15–21. https://doi.org/10.21518/2079-701X-2019-10-15-21.; Finn R.S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M. et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–358. https://doi.org/10.1016/j.jhep.2018.04.010.; El-Khoueiry A.B., Melero I., Yau T.C., Crocenziм T.S., Kudo M., Hsu C. et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate 040. J Clin Oncol. 2018;36(4_ suppl):475–475. https://doi.org/10.1200/JCO.2018.36.4_suppl.475.; Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, openlabel phase 2 trial. Lancet Oncol. 2018;19(7):940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.; Бредер В. В., Лактионов К.К. Вторая линия лечения гепатоцеллюлярного рака: от теории к практике. Медицинский совет. 2019;(19):30–36. https://doi.org/10.21518/2079-701X-2019-19-30-36.; Yau T., Park J.-W., Finn R.S., Cheng A.L., Mathurin P., Edeline J. et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(5 Suppl.) :v874–875. https://doi.org/10.1093/annonc/mdz394.029.; Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2.; Finn R.S., Ryoo B.-Y., Merle P., Kudo M., Bouattour M., Lim H.-Y. et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(15_suppl):516. https://doi.org/10.1200/JCO.2019.37.15_suppl.4004.; Llovet J.M., Montal R., Sia D., Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. https://doi.org/10.1038/s41571-018-0073-4.; Finn R.S., Ryoo B.-Y., Merle P., Kudo M., Bouattour M., Lim H.Y. et al. Pembrolizumab as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307.; Юдин Д.И., Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Борисова О.И., Ардзинба М.С. Псевдопрогрессирование на фоне иммунотерапии. Медицинский совет. 2019;(10):10–14. https://doi.org/10.21518/2079-701X-2019-10-10-14.; https://www.med-sovet.pro/jour/article/view/6593

الاتاحة: https://www.med-sovet.pro/jour/article/view/6593
https://doi.org/10.21518/2079-701X-2021-20-150-154

المؤلفون: A. Pitkevich A., V. Kosyrev Yu., I. Dzhanyan A., M. Novruzbekov S., A. Monakhov R., S. Zubenko I., S. Voskanyan E., V. Rudakov S., E. Moroz A., V. Breder V., М. Питкевич Ю., В. Косырев Ю., И. Джанян А., М. Новрузбеков С., А. Монахов Р., С. Зубенко И., С. Восканян Э., В. Рудаков С., Е. Мороз А., В. Бредер В.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 110-116 ; Медицинский Совет; № 20 (2021); 110-116 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: hepatocellular cancer, liver transplantation, neoadjuvant therapy, TACE, RFA, гепатоцеллюлярный рак, трансплантация печени, неоадъювантная терапия, ТАХЭ, РЧА

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6587/5970; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.; Marengo A., Rosso C,. Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117. https://doi.org/10.1146/annurev-med-090514-013832.; Chang M.-H., Chen C.-J., Lai M.-S., Hsu H.-M., Wu T.-C., Kong M.-Sh. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336(26):1855–1859. https://doi.org/10.1056/nejm199706263362602.; Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11(1):28–35. https://doi.org/10.1038/nrgastro.2013.179.; European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;48(5):599–641. https://doi.org/10.1016/j.ejca.2011.12.021.; Lang H., Sotiropoulos G.C., Dömland M., Frühauf N.R., Paul A., Hüsing J. et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Brit J Surg. 2005;92(2):198–202. https://doi.org/10.1002/bjs.4763.; Santambrogio R., Kluger M.D., Costa M., Belli A., Barabino M., Laurentet A. et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB. 2013;15(1):78–84. https://doi.org/10.1111/j.1477-2574.2012.00594.x.; Ercolani G., Grazi G.L., Ravaioli M., Gaudio M.D., Gardini A., Cescon M. et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536–543. https://doi.org/10.1097/01.sla.0000059988.22416.f2.; Wayne J.D., Gregory Y.L., Ikai I., Dorota A.D., Belghiti J., Yamaoka Y. et al. Preoperative predictors of survival after resectionn of small hepatocellular carcinomas. Ann Surg. 2002;235(5):722–730. https://doi.org/10.1097/00000658-200205000-00015.; Zheng Z., Liang W., Milgrom D.P., Zheng Z., Schroder P.M., Kong N.S. et al. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation. 2014;97(2):227–234. https://doi.org/10.1097/tp.0b013e3182a89383.; Tanaka S., Iimuro Yu., Hirano T., Hai S., Suzumura K., Nakamura I. et al. Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis. Surg Today. 2013;43(11):1290–1297. https://doi.org/10.1007/s00595-013-0706-2.; Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatology. 2014;2014:706945. https://doi.org/10.1155/2014/706945.; Lee Y.Ch., Chow P. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012;1(3–4):183–189. https://doi.org/10.1159/000343832. 14. Bruix J., Sherman M. Management of Hepatocellular Carcinoma: An update. Hepatology. 2011;53(3):1020–1022. https://doi.org/10.1002/hep.24199.; Alba E., Valls C., Dominguez J., Martinez L., Escalante E., Lladó L. et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol. 2008;190(5):1341–1348. https://doi.org/10.2214/AJR.07.2972.; Mazzaferro V., Battiston C., Perrone S., Pulvirenti A., Regalia E., Romito R. et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240(5):900–909. https://doi.org/10.1097/01.sla.0000143301.56154.95.; Lu D.S., Yu N.C., Raman S.S., Lassman C., Tong M.J., Britten C. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41(5):1130–1137. https://doi.org/10.1002/hep.20688.; Tsochatzis E., Garcovich M., Marelli L., Papastergiou V., Fatourou E., Rodriguez-Peralvarez M.L. et al. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013;33(6):944–949. https://doi.org/10.1111/liv.12144.; Freeman R.B., Steffick D.E., Guidinger M.K., Farmer D.G., Berg C.L., Merion R.M. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant. 2008;8(4 Pt 2):958–976. https://doi.org/10.1111/j.1600-6143.2008.02174.x.; Lai Q., Avolio A.W., Graziadei I., Otto G., Rossi M., Tisone G. et al. Alphafetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19(10):1108–1118. https://doi.org/10.1002/lt.23706.; Yao F.Y., Kerlan R.K., Hirose R., Davern T.J., Bass N.M., Feng S et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48(3):819–827. https://doi.org/10.1002/hep.22412.; De Carlis L., Di Sandro S., Giacomoni A., Slim A., Lauterio A., Mangoni I. et al. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol. 2012;46(1):78–86. https://doi.org/10.1097/mcg.0b013e31822b36f6.; Готье С.В., Монахов А.Р., Цирульникова О.М., Зубенко С.И., Ситникова Е.В., Умрик Д.В. и др. Результаты трансплантации печени при гепатоцеллюлярном раке: опыт одного центра. Анналы хирургической гепатологии. 2020;25(2):67–76. https://doi.org/10.16931/1995-5464.2020267-76.; Otto G., Herber S., Heise M., Lohse A.W., Mönch C., Bittinger F. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12(8):1260–1267. https://doi.org/10.1002/lt.20837 .; Graziadei I.W., Sandmueller H., Waldenberger P., Koenigsrainer A., Nachbaur K., Jaschke W. et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9(6):557–563. https://doi.org/10.1053/jlts.2003.50106.; Decaens T., Roudot-Thoraval F., Bresson-Hadni S., Meyer C., Gugenheim J., Durand F. et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2005;11(7):767–775. https://doi.org/10.1002/lt.20418.; Agopian V.G., Morshedi M.M., McWilliams J., Harlander-Locke M.P., Markovic D., Zarrinpar A. et al. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg. 2015;262(3):536–545. https://doi.org/10.1097/sla.0000000000001384.; Cescon M., Cucchetti A., Ravaioli M., Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58(3):609–618. https://doi.org/10.1016/j.jhep.2012.09.021.; Garwood E.R., Fidelman N., Hoch S.E., Kerlan R.K., Yao F.Y. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl. 2013;19(2):164–173. https://doi.org/10.1016/j.jhep.2012.09.021.; Hsin I.F., Hsu C.Y., Huang H.C., Huang Y.H., Lin H.C., Lee R.C. et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol. 2011;45(6):556–562. https://doi.org/10.1097/mcg.0b013e318210ff17.; Kothary N., Weintraub J.L., Susman J., Rundback J.H. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18(12):1517–1526. https://doi.org/10.1016/j. jvir.2007.07.035.; https://www.med-sovet.pro/jour/article/view/6587

الاتاحة: https://www.med-sovet.pro/jour/article/view/6587
https://doi.org/10.21518/2079-701X-2021-20-110-116

المؤلفون: I. Dzhanyan А., М. Natrusova V., V. Breder V., И. Джанян А., М. Натрусова В., В. Бредер В.

المصدر: Meditsinskiy sovet = Medical Council; № 4S (2021); 8-15 ; Медицинский Совет; № 4S (2021); 8-15 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: HCC, immunotherapy, atezolizumab, bevacizumab, anti-VEGF/PD-L1, cirrhosis, гепатоцеллюлярный рак, иммунотерапия, атезолизумаб, бевацизумаб, антиVEGF/PD-L1, цирроз печени

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6206/5644; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442.; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. 250 c. Режим доступа: https://glavonco.ru/ upload/pages/cancer-register/statistika_zabol_2017.pdf.; Imamura H., Matsuyama Y., Tanaka E., Ohkubo T., Hasegawa K., Miyagawa S. et al. Risk factors contributing to early and late phase intrahepatic recur rence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/s0168-8278(02)00360-4.; Boland P., Wu J. Systemic therapy for hepatocellular carcinoma: beyond sorafenib. Chin Clin Oncol. 2018;7(5):50. doi:10.21037/cco.2018.10.10.; Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857.; Kudo M., Finn R.S., Qin S., Han K., Ikeda K., Piscaglia F. et al. Lenvatinib ver sus sorafenib in first-line treatment of patients with unresectable hepato cellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1.; Yoong K.F., McNab G., Hübscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumorinfiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 1998;160(8):3978– 3988. Available at: https://pubmed.ncbi.nlm.nih.gov/9558106.; El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T., Kudo M., Hsu C. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2.; Yau T., Park J.W., Finn R.S., Cheng A., Mathurin P., Edeline J. et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(5 Suppl.):851–934. Available at: https://oncologypro.esmo.org/meeting-resources/esmo 2019-congress/CheckMate-459-A-Randomized-Multi-Center-Phase-3- Study-of-Nivolumab-NIVO-vs-Sorafenib-SOR-as-First-Line-1L-Treatment in-Patients-pts-With-Advanced-Hepatocellular-Carcinoma-aHCC.; Morse M.A., Sun W., Kim R., He A.R., Abada P.B., Mynderse M., Finn R.S. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254.; Zhu A.X., Duda D.G., Sahani D.V., Jain R.K. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301. doi:10.1038/nrclinonc.2011.30.; Motz G.T., Santoro S.P., Wang L.-P., Garrabrant T., Lastra R.R., Hagemann I.S. et al. Tumor endothelium FasL establishes a selective immune barrier promot ing tolerance in tumors. Nat Med. 2014;20(6):607–615. doi:10.1038/nm.3541.; Wallin J.J., Bendell J.C., Funke R., Sznol M., Korski K., Jones S. et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. doi:10.1038/ncomms12624.; Hegde P.S., Wallin J.J., Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt. 2):117–124. doi:10.1016/j.semcancer.2017.12.002.; Chen D.S., Hurwitz H. Combinations of bevacizumab with cancer immuno therapy. Cancer J. 2018;24(4):193–204. doi:10.1097/ PPO.0000000000000327.; Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011.; Finn R.S., Bentley G., Britten C.D., Amado R., Busuttil R.W. Targeting vascu lar endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int. 2009;29(2):284–290. doi:10.1111/j.1478-3231.2008.01762.x.; Boige V., Malka D., Bourredjem A., Dromain C., Baey C., Jacques N. et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–1072. doi:10.1634/theoncologist.2011-0465.; Siegel A.B., Cohen E.I., Ocean A., Lehrer D., Goldenberg A., Knox J.J. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992– 2998. doi:10.1200/JCO.2007.15.9947.; Thomas M.B., Garrett-Mayer E., Anis M., Anderton K., Bentz T., Edward A. et al. A randomized phase II open-label multi-institution study of the combi nation of bevacizumab and erlotinib compared to sorafenib in the first line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94(6):329–339. doi:10.1159/000485384.; Lee M.S., Ryoo B-Y., Hsu C.-H., Numata K., Stein S., Verret W. et al. Atezolizumab with or without bevacizumab in unresectable hepatocellu lar carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X.; Finn R.S., Qin S., Ikeda M., Qin S., Ikeda M., Galle P. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745.; Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y. et al. IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. In: Gastrointestinal Cancers Symposium. January 15–17, 2021. Available at: https://bit.ly/3m2WYcl.; Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913.; Ikeda M., Zhu A.X., Qin S., Kim T.-Y., Lim H.Y., Kudo M. et al. 1008P IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC. European Society for Medical Oncology (ESMO). Ann Oncol. 2020;31(4 Suppl.):698–699. doi:10.1016/j.annonc.2020.08.1124.; Lu L.C., Hsu C., Shao Y.Y., Chao Y., Yen C.J., Shih I.L. et al. Differential organ specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8(6):480–490. doi:10.1159/000501275.; https://www.med-sovet.pro/jour/article/view/6206

الاتاحة: https://www.med-sovet.pro/jour/article/view/6206
https://doi.org/10.21518/2079-701X-2021-4S-8-15

المؤلفون: M. Mandrina O., V. Breder V., M. Ivanov V., A. Lebedeva A., V. Gorbatsevich V., K. Laktionov K., P. Kononets V., М. Мандрина О., В. Бредер В., М. Иванов В., А. Лебедева А., В. Горбацевич В., К. Лактионов К., П. Кононец В.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2021); 154-159 ; Медицинский Совет; № 9 (2021); 154-159 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: MET mutation, PD-L1, immunotherapy, NSCLC, crizotinib, мутация MET, иммунотерапия, немелкоклеточный рак легкого, кризотиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6267/5681; König D., Savic Prince S., Rothschild S.I. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel). 2021;13(4):804. https://doi.org/10.3390/cancers13040804.; Socinski M.A., Pennell N.A., Davies K.D. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021;5:653–663. https://doi.org/10.1200/PO.20.00516.; Sierra J.R., Tsao M.S. c-MET as a Potential Therapeutic Target and Biomarker in Cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21–S35. https://doi.org/10.1177/1758834011422557.; Awad M.M., Oxnard G.R., Jackman D.M., Savukoski D.O, Hall D., Shivdasanietal P. et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016;34(7):721–730. https://doi.org/10.1200/JCO.2015.63.4600.; Titmarsh H.F., O’Connor R., Dhaliwal K., Akram A.R. The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy. Front Oncol. 2020;10:54. https://doi.org/10.3389/fonc.2020.00054.; Sabari J.K., Montecalvo J., Chen R., Dienstag J.A., Mrad C., Bergagnini I. et al. PD-L1 Expression and Response to Immunotherapy in Patients with MET Exon 14-Altered Non-Small Cell Lung Cancers (NSCLC). J Clin Oncol. 2017;35(15_ suppl):8512–8512. https://doi.org/10.1200/JCO.2017.35.15_suppl.8512.; Xing X., Guo J., Ding G., Li B., Dong B., Feng Q. et al. Analysis of PD1, PDL1, PDL2 Expression and T Cells Infiltration in 1014 Gastric Cancer Patients. Oncoimmunology. 2017;7(3):e1356144. https://doi.org/10.1080/2162402x.2017.1356144.; Glodde N., Bald T., van den Boorn-Konijnenberg D., Nakamura K., O’Donnell J.S., Szczepanski S. et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789.e9–802.e9. https://doi.org/10.1016/j.immuni.2017.09.012.; Papaccio F., Della Corte C.M., Viscardi G., Di Liello R., Esposito G., Sparano F. et al. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int J Mol Sci. 2018;19(11):3595. https://doi.org/10.3390/ijms19113595.; Salgia R., Sattler M., Scheele J., Stroh C., Felip E. The Promise of Selective MET Inhibitors in Non-Small Cell Lung Cancer with MET Exon 14 Skipping. Cancer Treat Rev. 2020;87:102022. https://doi.org/10.1016/j.ctrv.2020.102022.; Liang H., Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. Onco Targets Ther. 2020;13:2491–2510. https://doi.org/10.2147/OTT.S231257.; Garajová I., Giovannetti E., Biasco G., Peters G.J. c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015;7(Suppl 1):13–31. https://doi.org/10.4137/TOG.S30534.; Baltschukat S., Engstler B.S., Huang A., Hao H.X., Tam A., Wang H.Q. et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019;25(10):3164–3175. https://doi.org/10.1158/1078-0432.ccr-18-2814.; Klempner S.J., Borghei A., Hakimian B., Ali S.M., Ou S.I. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. J Thorac Oncol. 2017;12(1):152–156. https://doi.org/10.1016/j.jtho.2016.09.127.; Wang S.X.Y., Zhang B.M., Wakelee H.A., Koontz M.Z., Pan M., Diehn M. et al. Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small-Cell Lung Cancers with Response to Crizotinib and Cabozantinib. Anticancer Drugs. 2019;30(5):537–541. https://doi.org/10.1097/CAD.0000000000000765.; Waqar S.N., Morgensztern D., Sehn J. MET Mutation Associated with Responsiveness to Crizotinib. J Thorac Oncol. 2015;10(5):e29–e31. https://doi.org/10.1097/JTO.0000000000000478.; https://www.med-sovet.pro/jour/article/view/6267

الاتاحة: https://www.med-sovet.pro/jour/article/view/6267
https://doi.org/10.21518/2079-701X-2021-9-154-159

المؤلفون: В. Бредер В., И. Базин С., В. Косырев Ю., Е. Ледин В.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 452-467 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 452-467 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: рак билиарного тракта, внутрипеченочная холангиокарцинома, внепеченочная холангиокарцинома, опухоль Клацкина, рак желчного пузыря, химиотерапия, химиолучевая терапия, аблация, СА19-9

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/874/622; https://www.malignanttumors.org/jour/article/view/874

الاتاحة: https://www.malignanttumors.org/jour/article/view/874
https://doi.org/10.18027/2224-5057-2021-11-3s2-26

المؤلفون: В. Бредер В., П. Балахнин В., Э. Виршке Р., В. Косырев Ю., Е. Ледин В., В. Петкау В.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 431-451 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 431-451 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: гепатоцеллюлярный рак, фиброламеллярная карцинома, цирроз печени, BCLC, ТАХЭ, РЧА, аблация, иммунотерапия, атезолизумаб, бевацизумаб, сорафениб, регорафениб, ленватиниб, кабозантиниб, рамуцирумаб, ниволумаб, ипилимумаб, гепатит С, гепатит B, HCV, HBV, АФП

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/873/621; https://www.malignanttumors.org/jour/article/view/873

الاتاحة: https://www.malignanttumors.org/jour/article/view/873
https://doi.org/10.18027/2224-5057-2021-11-3s2-25

المؤلفون: К. Лактионов К., Е. Артамонова В., В. Бредер В., В. Горбунова А., Ф. Моисеенко В., Е. Реутова В., Д. Сакаева Д., А. Смолин В., М. Тер-Ованесов Д.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 36-54 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 36-54 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: немелкоклеточный рак легкого, аденокарцинома, неплоскоклеточный рак легкого, плоскоклеточный рак легкого, мутация EGFR, транслокация ALK, ROS1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/851/599; https://www.malignanttumors.org/jour/article/view/851

الاتاحة: https://www.malignanttumors.org/jour/article/view/851
https://doi.org/10.18027/2224-5057-2021-11-3s2-02

المؤلفون: Petkau, V. V., Breder, V. V., Bessonova, E. N., Tarkhanov, A. A., Петкау, В. В., Бредер, В. В., Бессонова, Е. Н., Тарханов, А. А.

مصطلحات موضوعية: HEPATOCELLULAR CARCINOMA (HCC), LIVER CANCER, EPIDEMIOLOGY, RISK FACTORS, MULTIDISCIPLINARY TEAM, ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК, РАК ПЕЧЕНИ, ЭПИДЕМИОЛОГИЯ, ФАКТОРЫ РИСКА, МУЛЬТИДИСЦИПЛИНАРНЫЙ КОНСИЛИУМ

وصف الملف: application/pdf

Relation: Scopus; Онкологическая помощь больным гепатоцеллюлярным раком в Свердловской области / В. В. Петкау, В. В. Бредер, Е. Н. Бессонова, А. А. Тарханов // Вопросы онкологии. - 2020. - Том 66. - № 4. - c.364-369.; http://elib.usma.ru/handle/usma/7177

الاتاحة: http://elib.usma.ru/handle/usma/7177

المؤلفون: Petkau, V. V., Breder, V. V., Bessonova, E. N., Laktionov, K. K., Stilidi, I. S., Петкау, В. В., Бредер, В. В., Бессонова, Е. Н., Лактионов, К. К., Стилиди, И. С.

مصطلحات موضوعية: HEPATOCELLULAR CARCINOMA (HCC), LIVER CANCER, COVID-19, CORONAVIRUS, TARGETED THERAPY, TRANSARTERIAL CHEMOEMBOLIZATION (TACE), ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК (ГЦР), РАК ПЕЧЕНИ, КОРОНАВИРУС, ТАРГЕТНАЯ ТЕРАПИЯ, ТРАНСАРТЕРИАЛЬНАЯ ХИМИОЭМБОЛИЗАЦИЯ (ТАХЭ)

وصف الملف: application/pdf

Relation: Scopus; Петкау В.В., Бредер В.В., Бессонова Е.Н., Лактионов К.К., Стилиди И.С. Онкологическая помощь больным гепатоцеллюлярным раком в условиях пандемии COVID-19. Обзор опубликованных исследований, рекомендаций и мнений профессиональных сообществ. Медицинский совет. 2020;(9):226–231.; http://elib.usma.ru/handle/usma/7166

الاتاحة: http://elib.usma.ru/handle/usma/7166

المؤلفون: T. Borisova N., A. Nazarenko V., K. Laktionov K., S. Tkachev I., S. Alieva B., V. Breder V., O. Trofimova P., V. Glebovskaya V., A. Fedorova A., D. Marinov T., N. Meshcheriakova A., S. Ivanov M., S. Gerasimov G., Т. Борисова Н., А. Назаренко В., К. Лактионов К., С. Ткачев И., С. Алиева Б., В. Бредер В., О. Трофимова П., В. Глебовская В., А. Федорова А., Д. Маринов Т., Н. Мещерякова А., С. Иванов М., С. Герасимов С.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 150-156 ; Медицинский Совет; № 20 (2020); 150-156 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: stereotactic radiotherapy, lung cancer, overall survival, disease-specific survival, radiation toxicity, predictor factors, стереотаксическая радиотерапия, рак легкого, общая выживаемость, опухоль-специфическая выживаемость, лучевая токсичность, предикторные факторы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5949/5430; Torre L.A., Bray F., Siegel R.L. Ferlay J., Lortet-Tieulent J., Jemal A. et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.; Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразова­ ния в России и странах СНГ в 2012 г. М.; 2014.; Pezzi C.M., Mallin K., Mendez A.S., Gau E.G., Putnam J.B. Jr. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg. 2014;148(5):2269–2277. doi:10.1016/j.jtcvs.2014.07.077.; Nanda R.H., Liu Y., Gillespie T.W., Mikell J.L., Ramalingam S.S., Fernandez F.G. et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer. 2015;121(23):4222–4230. doi:10.1002/cncr.29640.; Dalwadi S.M., Szeja S., Teh B.S., Balter E.B., Farach A.M. Outcomes in elderly stage I non-small cell lung cancer in the stereotactic body radiation therapy era: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2016;96(S2):S68. doi:10.1016/j.ijrobp.2016.06.174.; Haasbeek C.J., Lagerwaard F.J., Antonisse M.E., Slotman B.J., Senan S. Stage I nonsmall cell lung cancer in patients aged ≥75 years: outcomes after stereotactic radiotherapy. Cancer. 2010;116(2):406–414. doi:10.1002/cncr.24759.; Van den Berg L.L., Klinkenberg T.J., Groen H.J., Widder J. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. J Thorac Oncol. 2015;10(5):826–831. doi:10.1097/JTO.0000000000000483.; Chang J.Y., Senan S., Paul M.A., Mehran R.J., Louie A.V., Balter P. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637. doi:10.1016/S1470-2045(15)70168-3.; Давыдов М.И., Полоцкий Б.Е. Современные принципы выбора лечебной тактики и возможность хирургического лечения немелкоклеточного рака легкого. В: Переводчикова Н.И. (ред.). Новое в терапии рака легкого. М.; 2003.; Li L., Ren S., Zhang Y., Guan Y., Zhao J., Liu J. et al. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic. Lung Cancer. 2013;81(2):213–217. doi:10.1016/j.lungcan.2013.04.012.; Onishi H., Araki T., Shirato H., Nagata Y., Hiraoka M., Gomi K. et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623–1631. doi:10.1002/cncr.20539.; Katoh N., Soda I., Tamamura H., Takahashi S., Uchinami Y., Ishiyama H. et al. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumortracking radiotherapy system. Radiat Oncol. 2017;12(1):3–12. doi:10.1186/ s13014-016-0742-3.; Stanic S., Paulus R., Timmerman R.D., Michalski J.M., Barriger R.B., Bezjak A. et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88(5):1092–1099. doi:10.1016/j.ijrobp.2013.12.050.; Ferrero C., Badellino S., Filippi A.R., Focaraccio L., Levra M.G., Levis M. et al. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer. 2015;89(3):350–356. doi:10.1016/j.lung- can.2015.06.019.; Benedict S.H., Yenice K.M., Followill D., Calvin J.M., Hinson W., Kavanagh B. et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–4101. doi:10.1118/1.3438081.; Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–4839. doi:10.1200/JCO.2006.07.5937.; Aoki M., Sato M., Hirose K., Akimoto Y., Kawaguchi H., Hatayama Y. et al. Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size. Radiat Oncol. 2015;10:99–106. doi:10.1186/s13014-015-0406-8.; Park Y., Kim H.J., Chang A.R. Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors. Radiat Oncol. 2017;12(1):66. doi:10.1186/s13014-017-0857-1.; https://www.med-sovet.pro/jour/article/view/5949

الاتاحة: https://www.med-sovet.pro/jour/article/view/5949
https://doi.org/10.21518/2079-701X-2020-20-150-156

المؤلفون: V. Petkau V., V. Breder V., E. Bessonova N., K. Laktionov K., I. Stilidi S., В. Петкау В., В. Бредер В., Е. Бессонова Н., К. Лактионов К., И. Стилиди С.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 226-231 ; Медицинский Совет; № 9 (2020); 226-231 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: hepatocellular carcinoma (HCC), liver cancer, COVID-19, coronavirus, targeted therapy, transarterial chemoembolization (TACE), гепатоцеллюлярный рак (ГЦР), рак печени, коронавирус, таргетная терапия, трансартериальная химиоэмболизация (ТАХЭ)

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5739/5237; Lai C.C., Wang C.Y., Wang Y.H., Hsueh S.C., Ko W.C., Hsueh P.R. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. doi:10.1016/j.ijantimicag.2020.105946.; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7.; Moon A.M., Singal A.G., Tapper E.B. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2019;S1542– 3565(19):30849-3. doi:10.1016/j.cgh.2019.07.060.; Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3.; Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in coronavirus disease2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.017.; CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12 – March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–386. doi:10.15585/mmwr.mm6913e2.; Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648.; Shi H., Han X., Jiang N., Cao Y., Alwalid O., Gu J. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425–434. doi:10.1016/S1473-3099(20)30086-4.; Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585.; Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032.; Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5.; Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.; Xu X.W., Wu X.X., Jiang X.G., Xu K.J., Ying L.J., Ma C.L. et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi:10.1136/bmj.m606.; Mantovani A., Beatrice G., Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver Int. 2020;10.1111/ liv.14465. doi:10.1111/liv.14465.; Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X.; Kumar D., Tellier R., Draker R., Levy G., Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003;3(8):977–981. doi:10.1034/j.1600-6143.2003.00197.x.; Maggi U., De Carlis L., Yiu D., Michele C., Enrico R., Giorgio R. et al. The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy. Am J Transplant. 2020;10.1111/ajt.15948. doi:10.1111/ajt.15948.; Pereira M.R., Mohan S., Cohen D.J., Husain S.A., Dube G.K., Ratner L.E. et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. Am J Transplant. 2020;10.1111/ajt.15941. doi:10.1111/ajt.15941.; Liang W., Guan W., Chen R., Wang W., Li J., Xu K. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6.; Yu J., Ouyang W., Chua M.L.K., Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020;e200980. doi:10.1001/jamaoncol.2020.0980.; Zhang L., Zhu F., Xie L., Wang C., Wang J., Chen R. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. pii: S0923- 7534(20)36383-3. doi:10.1016/j.annonc.2020.03.296.; Xia Y., Jin R., Zhao J., Li W., Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e180. doi:10.1016/S1470-2045(20)30150-9.; Wang H., Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e181. doi:10.1016/S1470-2045(20)30149-2.; Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998–1004. doi:10.1111/liv.14435.; Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430. doi:10.1016/S2468-1253(20)30057-1.; Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D. et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020;8(1):18–24. doi:10.14218/JCTH.2020.00018.; Bangash M.N., Patel J., Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5:529–530. pii: S2468- 1253(20)30084-4. doi:10.1016/S2468-1253(20)30084-4.; Dong N., Yang X., Ye L. et. al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv. 2020. doi:10.1101/2020.01.20.913368.; Di Gennaro F., Pizzol D., Marotta C., Antunes M., Racalbuto V., Veronese N., Smith L. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. Int J Environ Res Public Health. 2020;17(8):2690. doi:10.3390/ijerph17082690.; Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:10.1172/JCI138003.; Ghosh A.K., Brindisi M., Shahabi D., Chapman M.E., Mesecar A.D. Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem. 2020. doi:10.1002/cmdc.202000223.; Meyer T., Chan S., Park J.W. International Liver Cancer Association (ILCA) Guidance for Management of HCC during COVID­19 Pandemic. 8th April 2020. Available at: https://ilca-online.org/management-of-hcc-during-covid-19-ilca-guidance/.; Fix O.K., Hameed B., Fontana R.J., Kwok R.M., McGuire B.M., Mulligan D.C. et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020. doi:10.1002/hep.31281.; Boettler T., Newsome P.N., Mondelli M.U., Maticic M., Cordero E., Cornberg M., Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113.; Kadalayil L., Benini R., Pallan L., O’Beirne J., Marelli L., Yu D. et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–2570. doi:10.1093/annonc/mdt247.; Kudo M., Ueshima K., Chan S. et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel). 2019;11(8). pii: E1084. doi: https://doi.org/10.3390/cancers11081084.; Lammer J., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A. et al.; PRECISION V Investigators. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. doi:10.1007/s00270-009-9711-7.; Meyer T., Kirkwood A., Roughton M., Beare S., Tsochatzis E., Yu D. et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–1259. doi:10.1038/bjc.2013.85.; Smith T., Bushek J., LeClaire A., Prosser T. COVID­19 Drug Therapy. Elsevier; 2020. Available at: https://www.elsevier.com/__data/assets/pdf_file/0016/1004173/COVID-19-Drug-Therapy_5.22.2020.pdf.; Cortegiani A., Ingoglia G., Ippolito M., Iarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283. doi:10.1016/j.jcrc.2020.03.005.; Bruix J., Qin S., Merle P., Granito A., Huang Y.H., Bodoky G. et al.; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9.; Chen J., Wang J. Risk of regorafenib-induced cardiovascular events in patients with solid tumors. A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(41):e12705. doi:10.1097/MD.0000000000012705.; https://www.med-sovet.pro/jour/article/view/5739

الاتاحة: https://www.med-sovet.pro/jour/article/view/5739
https://doi.org/10.21518/2079-701X-2020-9-226-231

المؤلفون: K. Sarantseva A., K. Laktionov K., E. Reutova V., D. Yudin I., V. Breder V., К. Саранцева А., К. Лактионов К., Е. Реутова В., Д. Юдин И., В. Бредер В.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 194-198 ; Медицинский Совет; № 20 (2020); 194-198 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: EGFR tyrosine kinase inhibitors, osimertinib, metastases, brain, lung cancer, non-small cell lung cancer, ингибиторы тирозинкиназы EGFR, осимертиниб, метастазы, головной мозг, рак легкого, немелкоклеточный рак легкого

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5956/5436; Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874. doi:10.1200/JCO.2010.33.4235.; Zhou C., Wu Y.L., Chen G., Feng J., Liu X.-Q., Wang C. et al. Erlotinib versus chemotherapy as first‐line treatment for patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer (OPTIMAL, CTONG‐0802): a multicentre, open‐label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X.; Реутова Е.В., Лактионов К.П., Юдин Д.И., Нелюбина Л.А., Горохова Г.К., Егорова А.В. Осимертиниб в 1-й линии терапии EGFR-позитивного немелкоклеточного рака легкого. Современная онкология. 2019;21(3):17–20. doi:10.26442/18151434.2019.3.190659.; Mok T.S., Wu Y.-L., Ahn M.-J., Garassino M.C., Kim H.R., Ramalingam S.S. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674.; Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137.; Ramalingam S.S., Vansteenkiste J., Planchard D., Cho B.C., Gray J.E., Ohe Y. et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662.; Suda K., Mizuuchi H., Maehara Y., Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation – diversity, ductility, and destiny. Cancer Metastasis Rev. 2012;31(3–4):807–814. doi:10.1007/s10555-012-9391-7.pub4.; Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc2088.; Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W. et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. NEJM. 2004;350(21):2129–2139. doi:10.1056/NEJMoa040938.; Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi:10.1126/science.1099314.; Cheng L., Alexander R.E., Maclennan G.T., Cummings O.W., Montironi R., LopezBeltran A. et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25(3):347–369. doi:10.1038/modpathol.2011.215.; Tjulandin S., Imyanitov E., Moiseyenko V., Ponomarenko D., Gurina L., Koroleva I., Karaseva V. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin. 2015;31(6):1117–1127. doi:10.1185/03007995.2015.1036015.; Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4 Suppl.):iv192–iv237. doi:10.1093/annonc/mdy275.; Ballard P., Yates J.W., Yang Z., Kim D.W., Yang J.C., Cantarini M. et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22(20):5130–5140. doi:10.1158/1078-0432.CCR-16-0399.; Togashi Y., Masago K., Masuda S., Mizuno T., Fukudo M., Ikemi Y. et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70:399–405. doi:10.1007/s00280-012-1929-4.; Hoffknecht P., Tufman A., Wehler T., Pelzer T., Wiewrodt R., Schütz M. et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-smallcell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–163. doi:10.1097/JTO.0000000000000380.; Batra U., Lokeshwar N., Gupta S., Shirsath P. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients. Indian J Cancer. 2017;54(Suppl.):S37–S44. doi:10.4103/ijc.IJC_532_17.; Park S.J., Kim H.T., Lee D.H., Kim K.P., Kim S.W., Suh C., Lee J.S. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556–560. doi:10.1016/j.lungcan.2012.05.092.; Lee Y.J., Choi H.J., Kim S.K., Chang J., Moon J.W., Park I.K. et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall cell lung cancer. Cancer. 2010;116(5):1336–1343. doi:10.1002/cncr.24877.; Peters S., Bexelius C., Munk V., Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–162. doi:10.1016/j.ctrv.2016.03.009.; Goss G., Tsai C.M., Shepherd F.A., Ahn M.J., Bazhenova L., Crinò L. et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29(3):687–693. doi:10.1093/annonc/mdx820.; Wu Y.L., Ahn M.J., Garassino M.C., Han J.Y., Katakami N., Kim H.R. et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced NonSmall-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018;36(26):2702–2709. doi:10.1200/JCO.2018.77.9363.; Yang J.C., Ahn M.J., Kim D.W., Ramalingam S.S., Sequist L.V., Su W.C. et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017;35(12):1288–1296. doi:10.1200/JCO.2016.70.3223.; Goss G., Tsai C.M., Shepherd F.A., Bazhenova L., Lee J.S., Chang G.C. et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-smallcell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652. doi:10.1016/S1470-2045(16)30508-3.; Reungwetwattana T., Nakagawa K., Cho B.C., Cobo M., Cho E.K., Bertolini A. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with Untreated EGFRMutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(33):3290–3297. doi:10.1200/JCO.2018.78.3118.; Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M. et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8(2):185–191. doi:10.1097/JTO.0b013e3182773f21.; https://www.med-sovet.pro/jour/article/view/5956

الاتاحة: https://www.med-sovet.pro/jour/article/view/5956
https://doi.org/10.21518/2079-701X-2020-20-194-198

المؤلفون: E. Antonova Yu., V. Breder V., E. Moroz A., K. Laktionov K., I. Dzhanyan A., A. Volkov Yu., Е. Антонова Ю., В. Бредер В., Е. Мороз А., К. Лактионов К., Н. Джанян А., А. Волков Ю.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 134-142 ; Медицинский Совет; № 20 (2020); 134-142 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: fibrolamellar liver carcinoma, liver cancer, large tumor cells, DNAJB1-PRKCА, фиброламеллярная карцинома печени, рак печени, крупные опухолевые клетки

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5948/5429; Edmonson H.A. Differential diagnosis of tumors and tumor – like lesion of liver in infancy and childhood. AMA Am Arch Dis Child. 1956;91(2):168– 186. doi:10.1001/archpedi.1956.02060020170015.; Craig J.R., Peters R.L., Edmondson H.A. Omata M. Fibrolamel – lar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer. 1980;46(2):372–379. doi:10.1002/1097-0142(19800715)46:23.0.co;2-s.; Berman M.M., Libbey P., Foster J.H. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma–an atypical variant with a favorable prognosis. Cancer. 1980;46(6):1148–1155. doi:10.1002/1097-0142(19800915)46:63.0.co;2-j.; Ringe B., Wittekind C., Weimann A., Tusch G., Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175(4):299–305. Available at: https://pubmed.ncbi.nlm.nih.gov/1329242/.; Pinna A.D., Iwatsuki S., Lee R.G., Todo S., Madariaga J.R., Marsh J.W. et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy of transplantation. Hepatology. 1997;26(4):877–83. doi:10.1002/hep.510260412.; El-Gazzaz G., Wong W., El-Hadary M.K., Gunson B.K., Mirza D.F., Mayer A.D. et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(1 Suppl.):S406–S409. Available at: https://pubmed.ncbi.nlm.nih.gov/11112043/; El-Serag H.B., Davila J.A. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803. doi:10.1002/hep.20096.; Moreno-Luna L.E., Arrieta O., García-Leiva J., Мartínez В., Torre А., Uribe М., León-Rodríguez E. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005;5:142. doi:10.1186/1471-2407-5-142.; Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006 Mar 15;106(6):1331-8. doi:10.1002/cncr.21703. PMID: 16475212. doi:10.1002/cncr.21703.; Kaseb А.О., Shama М., Sahin I.H., Nooka А., Hassabo H.M., Vauthey J.-N. et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85(4):197–203. doi:10.1159/000354698.; Cronin K.A., Ries L.A., Edwards B.K. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014;120(S23):S3755–S3757. doi:10.1002/cncr.29049.; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные ново­ образования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.; Mavros M.N., Mayo S.C., Hyder O., Pawlik T.M. A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820–830. doi:10.1016/j.jamcoll- surg.2012.08.001.; Hemming A.W., Langer B., Sheiner P., Greig P.D., Taylor B.R. Aggressive surgical management of f ibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1(4):342–346. doi:10.1016/s1091-255x(97)80055-8.; Алиева С.Б., Бредер В.В. и др. Клинические рекомендации АОР 2019 г. Рак печени (гепатоцеллюлярный). Режим доступа: https://oncology-association.ru/files/new-clinical-guidelines/rak_pecheni.pdf.; Greene F.L., Sobin L.H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008;58(3):180–190. doi:10.3322/CA.2008.0001.; Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K. et.al The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more «personalized» approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388.; Eggert T., McGlynn K.A., Duffy A., Manns M.P., Greten T.F., Altekruse S.F. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J. 2013;1(5):351–357. doi:10.1177/2050640613501507.; Lee C.W., Chan K.M., Lee C.F., Yu M.C., Lee W.C., Wu T.J., Chen M.F. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg. 2011;34(2):53–62. doi:10.1016/S1015-9584(11)60020-1.; Watanabe J., Nakashima O., Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol. 1994;24(1):37–41. Available at: https://pubmed.ncbi.nlm.nih.gov/8126919/.; Liu S., Chan K.W., Wang B., Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009;104(10):2617–2625. Available at: https://pubmed.ncbi.nlm.nih.gov/19638962/; Pérez-Guillermo M., Masgrau N.A., García-Solano J., Sola-Pérez J., de Agustín y de Agustín P. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. 1999;21(3):180–187. doi:10.1002/(sici)1097-0339(199909)21:33.0.co;2-o.; Torbenson M.S. Review of the Clinicopathologic Features of Fibrolamellar Carcinoma. Adv Anat Pathol. 2007;14:217–223. doi:10.1097/PAP.0b013e3180504913.; Torbenson M.S. Morphologic Subtypes of Hepatocellular Carcinoma, Gastroenterol. Clin N Am. 2017;46(2):365–391. doi:10.1016/j.gtc.2017.01.009.; Kitabayashi К., Yokoi М., Ueno K.-I., Saito H., Takashima S., Kurose N., Nojima T. Fibrolamellar hepatocellular carcinoma: report of a case. Hepatogastroenterology. 2003;50(54):1886–1888. Available at: https://pubmed.ncbi.nlm.nih.gov/14696425/.; Chaudhari V.A., Khobragade K., Bhandare M., Shailesh V. Shrikhande. Management of fibrolamellar hepatocellular carcinoma. Chinese Clinical Oncology. 2018;7(5):51. doi:10.21037/cco.2018.08.08.; Ward S.C., Huang J., Tickoo S.K., Thung S.N., Ladanyi M., Klimstra D.S. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23(9):1180–1190. doi:10.1038/modpathol.2010.105.; de Boer C.J., van Krieken J.H.J.M., Janssen-van Rhijn C.M., Litvinov S.V. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999;188(2):201–206. doi:10.1002/(SICI)1096-9896(199906)188:23.0.CO;2-8.; Gires O. EpCAM in hepatocytes and their progenitors. J Hepatol. 2012:56(2):490–492. doi:10.1016/j.jhep.2011.05.036.; Sergi C.M. Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer Diagnostics. 2015;6(1):3. doi:10.3390/diagnostics6010003.; Graham R.P., Torbenson M.S. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings. Semin Diagn Pathol. 2017;34(2):146–152. doi:10.1053/j.semdp.2016.12.010.; Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I. et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma. Science. 2014;343(6174):1010–1014. doi:10.1126/science.1249484.; N. Graham R.P., Jin L., Knutson D.L., Kloft-Nelson S.M., Greipp P.T., Waldburger et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology. 2015;28(6):822–829. doi:10.1038/modpathol.2015.4.; Dinh T.A., Vitucci E.C.M, Wauthier E., Graham R.P., Pitman W.A., Oikawa Т. et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep. 2017;7:44653. doi:10.1038/srep44653.; Vivekanandan P., Micchelli S.T., Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol. 2009;40(3):293–299. doi:10.1016/j.humpath.2008.08.003.; Simon E.P., Freije C.A., Farber B.A., Lalazar G., Darcy D.G., Honeyman J.N. et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci. 2015;112(44):E5916–E5925. doi:10.1073/pnas.1424894112.; Orsatti G., Hytiroglou P., Thung S.N., Ishak K.G., Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17(3):152–156. doi:10.1111/j.1600-0676.1997.tb00798.x.; Buckley A.F., Burgart L.J., Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37(4):410–414. doi:10.1016/j.humpath.2005.12.009.; Kannangai R., Sahin F., Torbenson M.S. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 2006;19:1456–1461. doi:10.1038/modpathol.3800665.; Kannangai R., Vivekanandan Р., Martinez-Murillo F., Choti M., Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. 2007;38(4):639–644. doi:10.1016/j.humpath.2006.07.019.; Torbenson M., Kannangai R., Abraham S., Sahin F., Choti M., Wang J. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma. Am J Clin Pathol. 2004;122(3):377–382. doi:10.1309/YH0H-3FKY-M4RM-U1JF.; Sorenson E.C., Khanin R., Bamboat Z.M., Cavnar M.J., Kim T.S. et al. Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. PLoS One. 2017;12(5):0176562. doi:10.1371/journal.pone.0176562.; Darcy D.G., Malek M.M., Kobos R., Klimstra D.S., DeMatteo R., La Quaglia M.P. Prognostic factors in fibrolamellar hepatocellular carcinoma in young adults. J Pediatr Surg. 2015;50(1):153–156. doi:10.1016/j.jpedsurg.2014.10.039.; Ang C.S., Kelley R.K., Choti M.A., Cosgrove D.P., Chou J.F., Klimstra D. et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3–9. Available at: https://pubmed.ncbi.nlm.nih.gov/23505572/; Dahan M.H., Kastell P. Fibrolamellar hepatic carcinoma with a presentation similar to that of septic pregnancy. A case report. J Reprod Med. 2002;47(1):47–49. Available at: https://www.pubfacts.com/detail/11838311/Fibrolamellar-hepatic-carcinoma-with-a-presentation-similar-to-that-of-septic-pregnancy-A-case-repor.; Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica. 2012;2012:743790. doi:10.6064/2012/743790.; Lloreta J., Vadell C., Fabregat X., Serrano S. Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid. Ultrastruct Pathol. 1994;18(1–2):287–292. doi:10.3109/01913129409016302.; Friedman A.C., Lichtenstein J.E., Goodman Z., Fishman E.K., Siegelman S.S., Dachman A.H. Fibrolamellar hepatocellular carcinoma. Radiology. 1985;157(3):583–587. doi:10.1148/radiology.157.3.2997835.; Ichikawa T., Federle M.P., Grazioli L., Madariaga J., Nalesnik M., Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. 1999;213(2):352–361. doi:10.1148/radiology.213.2.r99nv31352.; Brandt D.J., Johnson C.D., Stephens D.H., Weiland L.H. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 1988;151(2):295–299. doi:10.2214/ajr.151.2.295.; Kadoya M., Matsui O., Takashima T., Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology. 1992;183(3):819–825. doi:10.1148/radiology.183.3.1316622.; Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate disodiumenhanced MRI of the liver. Part 1, Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol. 2010;195(1):13–28. doi:10.2214/AJR.10.4392.; Palm V., Sheng R., Mayer P., Weiss K.H., Springfeld C., Mehrabi A. et al. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. Cancer Imaging. 2018;18:9. doi:10.1186/s40644-018- 0143-y.; Badiee S., Franc B.L., Webb E.M., Chu B., Hawkins R.A., Coakley F. Role of IV iodinated contrastmaterial in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol. 2008;191(5):1436–1439. doi:10.2214/AJR.07.3750.; Mayo S.C., Mavros M.N., Nathan H., Cosgrove D., Herman J.M., Kamel I. et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014;218(2):196–205. doi:10.1016/j.jamcollsurg.2013.10.011.; McAteer J.P., Goldin A.B., Healey P.J., Gow K.W. Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. J Pediatr Surg. 2013;48(11):2194–2201. doi:10.1016/j.jpedsurg.2013.05.007.; Amini N., Ejaz A., Spolverato G., Maithel S.K., Kim Y., Pawlik T.M. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18(12):2136–2148. doi:10.1007/s11605-014-2667-1.; Yamashita S., Vauthey J.N., Kaseb A.O., Aloia T.A., Conrad C., Hassan M.M. et al. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg. 2016;20(10):1725–1731. doi:10.1007/s11605-016-3216-x.; Njei B., Konjeti V.R., Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointest Cancer Res. 2014;7(2):49–54. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676/.; Fouzas I., Sotiropoulos G.C., Molmenti E.P., Beckebaum S., Schmitz K.J., Broelsch C.E. et al. «Preemptive» live donor liver transplantation for fibrolamellar hepatocellular carcinoma: A case report. Transplant Proc. 2008;40(10):3806–3807. doi:10.1016/j.transproceed.2008.09.050.; Atienza L.G., Berger J., Mei X., Shah M.B., Daily M.F., Grigorian A., Gedaly R. Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective. J Surg Oncol. 2017;115(3):319–323. doi:10.1002/jso.24515.; Peacock J.G., Call J.A., Olivier K.R. Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma. Rare Tumors. 2013;5(3):e28. doi:10.4081/rt.2013.e28.; Mafeld S., French J., Tiniakos D., Haugk B., Manas D., Littler P. Fibrolamellar hepatocellular carcinoma: treatment with yttrium-90 and subsequent surgical resection. Cardiovasc Intervent Radiol. 2018;41(5):816–820. doi:10.1007/s00270-018-1903-6.; Czauderna P., Zbrzezniak G., Narozanski W., Korzon M., Wyszomirska M., Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer. 2006;46(7):825–828. Available at: https://pubmed.ncbi.nlm.nih.gov/16123986/.; Fonseca G.M., Varella A.D., Coelho F.F., Abe E.S., Dumarco R.B., Herman P. Fibrolamellar hepatocellular carcinoma downstaging. World J Gastrointest Surg. 2014;6(6):107–111. doi:10.4240/wjgs.v6.i6.107.; Chakrabarti S., Tella S.H., Kommalapati A., Huffman B.M., Yadav S., Riaz I.B. et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(3):554–561. doi:10.21037/jgo.2019.01.35.; Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., Ellis L.M. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21(3):421–427. doi:10.1200/JCO.2003.10.103.; Weeda V.B., Murawski M., McCabe A.J., Maibach R., Brugières L., Roebuck D. et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013;49(12):2698–2704. doi:10.1016/j.ejca.2013.04.012.; Gras P., Truant S., Boige V., Ladrat L., Rougier P., Pruvot F.R., Hebbar M. Prolonged Complete Response after GEMOX chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol. 2012;5(1):169–172. doi:10.1159/000338242.; Riehle K.J., Yeh M.M., Yu J.J., Kenerson H.L., Harris W.P., Park J.O., Yeung R.S. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol. 2015;28(1):103–110. doi:10.1038/modpathol.2014.78.; Benito V., Segura J., Martínez M.S., Arencibia O., Lubrano A. Fibrolamellar Hepatocellular Carcinoma Metastatic to the Ovary. Obstet Gynaecol. 2012;32(2):200–202. doi:10.3109/01443615.2011.621558.; Nowak A.K., Findlay M., Culjak G., Stockler M.R. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev. 2020;(8):CD001024. doi:10.1002/14651858.; Bauer U., Mogler C., Braren R.F., Algül H., Schmid R.M., Ehmer U. Progression after Immunotherapy for Fibrolamellar Carcinoma. Visc Med. 2019;35(1):39–42. doi:10.1159/000497464.; https://www.med-sovet.pro/jour/article/view/5948

الاتاحة: https://www.med-sovet.pro/jour/article/view/5948
https://doi.org/10.21518/2079-701X-2020-20-134-142

المؤلفون: A. Kuzminov E., T. Borisova N., V. Breder V., E. Reutova V., T. Barbolina D., K. Laktionov K., А. Кузьминов Е., Т. Борисова Н., В. Бредер В., Е. Реутова В., Т. Барболина Д., К. Лактионов К.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 190-195 ; Медицинский Совет; № 9 (2020); 190-195 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: localized small cell lung cancer, prophylactic brain irradiation, early chemoradiotherapy, late chemoradiotherapy, simultaneous chemoradiotherapy, consecutive chemoradiotherapy, локализованный мелкоклеточный рак легкого, профилактическое облучение головного мозга, ранняя химиолучевая терапия, поздняя химиолучевая терапия, одновременная химиолучевая терапия, последовательная химиолучевая терапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5735/5233; Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–895. doi:10.1200/JCO.1992.10.6.890.; Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–1624. doi:10.1056/NEJM199212033272302.; Fried D.B., Morris D.E., Poole C., Rosenman J.G., Halle J.S., Detterbeck F.C. et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837–4845. doi:10.1200/JCO.2004.01.178.; Stinchcombe T.E., Gore E.M. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187–195. doi:10.1634/theoncologist.2009-0298.; Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C. et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11(2):336–344. doi:10.1200/JCO.1993.11.2.336.; Pijls-Johannesma M., De Ruysscher D., Vansteenkiste J., Kester A., Rutten I., Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007;33(5):461–473. doi:10.1016/j.ctrv.2007.03.002.; Spiro S.G., James L.E., Rudd R.M., Trask C.W., Tobias J.S., Snee M. et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006;24(24):3823–3830. doi:10.1200/JCO.2005.05.3181.; Schild S.E., Bonner J.A., Shanahan T.G., Brooks B.J., Marks R.S., Geyer S.M. et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59(4):943–951. doi:10.1016/j.ijrobp.2004.01.055.; De Ruysscher D., Lueza B., Le Péchoux C., Johnson D.H., O’Brien M., Murray N. et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818–1828. doi:10.1093/annonc/mdw263.; De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., Minken A., Wanders R., Lutgens L. et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24(7):1057–1063. doi:10.1200/JCO.2005.02.9793.; Bonner J.A., Sloan J.A., Shanahan T.G., Brooks B.J., Marks R.S., Krook J.E. et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681–2681. doi:10.1200/JCO.1999.17.9.2681.; Kies M.S., Mira J.G., Crowley J.J., Chen T.T., Pazdur R., Grozea P.N. et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reducedfield radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5(4):592–600. doi:10.1200/JCO.1987.5.4.592.; Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited smallcell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271. doi:10.1056/NEJM199901283400403.; Faivre-Finn C., Snee M., Ashcroft L., Ashcroft L., Appel W., Barlesi F. et al. Concurrent Once-Daily Versus Twice-Daily Chemoradiotherapy in Patients With Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3, Randomised, Superiority Trial Lancet Oncol. 2017;18(8):1116– 1125. doi:10.1016/S1470-2045(17)30318-2.; Arriagada R., Le Chevalier T., Borie F., Rivière A., Chomy P., Monnet I. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183–190. doi:10.1093/jnci/87.3.183.; Aupérin A., Arriagada R., Pignon J.P., Le Péchoux С., Gregor A., Stephens R.J. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–484. doi:10.1056/NEJM199908123410703.; Wolfson A.H., Bae K., Komaki R., Meyers С., Movsas В., Le Pechoux С. et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84. doi:10.1016/j.ijrobp.2010.05.013.; Zhang W., Jiang W., Luan L., Wang L., Zheng X., Wang G. Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2014;14:793. doi:10.1186/1471-2407-14-793.; Sun A., Bae K., Gore E.M., Movsas B., Wong S.J., Meyers C.A., Bonner J.A. et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non–small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2010;29(3):279– 286. doi:10.1200/JCO.2010.29.6053.; Gondi V., Paulus R., Bruner D.W., Meyers C.A., Gore E.M., Wolfson A. et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656–664. doi:10.1016/j.ijrobp.2013.02.033.; Le Péchoux C., Dunant A., Senan S., Wolfson A., Quoix E., Faivre-Finn C. et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003- 08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–474. doi:10.1016/S1470-2045(09)70101-9.; https://www.med-sovet.pro/jour/article/view/5735

الاتاحة: https://www.med-sovet.pro/jour/article/view/5735
https://doi.org/10.21518/2079-701X-2020-9-190-195

المؤلفون: D. Yudin I., K. Laktionov K., K. Sarantseva A., O. Borisova I., V. Breder V., E. Reutova V., M. Beloyartseva F., S. Kruteleva Yu., I. Dzhanyan A., Д. Юдин И., К. Лактионов К., К. Саранцева А., О. Борисова И., В. Бредер В., Е. Реутова В., М. Белоярцева Ф., С. Крутелева Ю., И. Джанян А.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 16-24 ; Медицинский Совет; № 9 (2020); 16-24 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: immune-related endocrinopathy, immunotherapy, checkpoint inhibitors, anti-CTLA-4, anti-PD-1/PD-L1, иммуноопосредованная эндокринопатия, иммунотерапия, ингибиторы контрольных точек, анти-CTLA-4, анти-PD-1/PD-L1

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5697/5195; Horn L., Gettinger S.N., Gordon M.S., Herbst R.S., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018;101:201–209. doi:10.1016/j.ejca.2018.06.031.; Antonia S.J., Borghaei H., Ramalingam S.S., Horn L., de Castro Carpeño J., Pluzanski A. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408. doi:10.1016/S1470-2045(19)30407-3.; Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M. et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced NonSmall-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412.; Fogt S., Shustova M., Demidov L.V., Moiseyenko V., Tjulandin S., Semiglazova T. et al. Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma. J Clin Oncol. 2019;37(15):9549. doi:10.1200/JCO.2019.37.15_suppl.9549.; Vaishampayan U., Schöffski P., Ravaud A., Borel C., Peguero J., Chaves J. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):275. doi:10.1186/s40425-019-0746-2.; Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1. doi:10.1186/s40842-018-0073-4.; Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.; Weber J., Mandala M., del Vecchio M., Gogas H.J., Arance A.M., Cowey C.L. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824–1835. doi:10.1056/NEJMoa1709030.; Garon E.B., Hellmann M.D., Rizvi N.A., Carcereny E., Leighl N.B., Ahn M.J. et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518–2527. doi:10.1200/JCO.19.00934.; Hellmann M.D., Ciuleanu T.-E., Pluzanski A., Lee J.S., Otterson G.A., AudigierValette C. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093–2104. doi:10.1056/NEJMoa1801946.; Mok T.S.K., Wu Y.L., Kudaba I., Kowalski D.M., Cho B.C., Turna H.Z. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi: doi:10.1016/S0140-6736(18)32409-7.; Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948.; Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937.; Morganstein D.L., Lai Z., Spain L., Diem S., Levine D., Mace C. et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86(4):614–620. doi:10.1111/cen.13297.; Robert C., Joshua A.M., Kefford R., Joseph R.W., Wolchok J.D., Hodi F.S. et al. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. Journal of Clinical Oncology. 2015;33(15):9050. doi:10.1200/jco.2015.33.15_suppl.9050.; McMillen B., Dhillon M.S., Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;2016:10.1136/bcr-214603. doi:10.1136/bcr-2016-214603.; Win M.A., Thein K.Z., Qdaisat A., Yeung S.J. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017;35(7):1039.e5–1039.e7. doi:10.1016/j.ajem.2017.02.048.; Trinh B., Sanchez G.O., Herzig P., Läubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer. 2019;7(1):52. doi:10.1186/s40425-019-0528-x.; Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Metaanalysis. JAMA Oncol. 2018;4(2):173–182. doi:10.1001/jamaoncol.2017.3064.; Paepegaey A.C., Lheure C., Ratour C., Lethielleux G., Clerc J., Bertherat J. et al. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. J Endocr Soc. 2017;1(6):646–649. doi:10.1210/js.2017-00170.; Dillard T., Yedinak C.G., Alumkal J., Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29–38. doi:10.1007/s11102-009-0193-z.; Torino F., Barnabei A., De Vecchis L., Salvatori R., Corsello S.M. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17(4):525–535. doi:10.1634/theoncologist.2011-0404.; Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–1375. doi:10.1210/jc.2012-4075.; Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593–598. doi:10.1097/01. cji.0000178913.41256.06.; Albarel F., Gaudy C., Castinetti F., Carré T., Morange I., Conte-Devolx B. et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195–204. doi:10.1530/EJE-14-0845.; Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin Cancer Res. 2015;21(4):749–755. doi:10.1158/1078-0432.CCR-14-2353.; Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J. et al. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocrinol Metab. 2018;103(2):365–369. doi:10.1210/jc.2017-01905.; Barroso-Sousa R., Ott P.A., Hodi F.S., Kaiser U.B., Tolaney S.M., Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018;124(6):1111–1121. doi:10.1002/cncr.31200.; Clotman K., Janssens K., Specenier P., Weets I., De Block C.E.M. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103(9):3144–3154. doi:10.1210/jc.2018-00728.; Shamy T.A., Aguasvivas M., Serhan M., Fojas M.M. Diabetic Ketoacidosis Triggered by Pembrolizumab in a Patient with Bladder Cancer. Diabetes. 2018;67(1):219–LB. doi:10.2337/db18-219-LB.; Maamari J., Yeung S.J., Chaftari P.S. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med. 2019;37(2):376.e1–376.e2. doi:10.1016/j.ajem.2018.10.040.; https://www.med-sovet.pro/jour/article/view/5697

الاتاحة: https://www.med-sovet.pro/jour/article/view/5697
https://doi.org/10.21518/2079-701X-2020-9-16-24

المؤلفون: K. Laktionov K., K. Sarantseva A., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., К. Лактионов К., К. Саранцева А., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 16-21 ; Медицинский Совет; № 19 (2019); 16-21 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: immunotherapy, non-small cell lung cancer, checkpoint inhibitors, nivolumab, иммунотерапия, немелкоклеточный рак легкого, ингибиторы контрольных точек, ниволумаб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5036/4585; Gettinger S., Horn L., Jackman D. at al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology 2018;36(17):JCO2017770412.·doi:10.1200/JCO.2017.77.0412.; Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: TwoYear Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933. doi:. 10.1200/JCO.2017.74.3062; Reck M., Taylor F., Penrod J.R., DeRosa M., Morrissey L., Dastani H., Orsini L., Gralla R.J. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 201813(2):194-204. doi:10.1016/j.jtho.2017.10.029.; Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Юдин Д.И., Лактионова Л.В. Результаты применения ниволумаба у больных с немелкоклеточным раком легкого в клинической практике. Вопросы онкологии. 2017;63(5):724-728.; Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016;(3):17-24. doi:10.18027/2224-5057-2016-3-17-24.; Burstein H.J., Krilov L., Aragon-Ching J.B., Baxter N.N., Chiorean E.G., Chow W.A. et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341-1367. doi:10.1200/JCO.2016.71.5292.; Chae Y.K., Pan A., Davis A.A., Raparia K., Mohindra N.A., Matsangou M., Giles F.J. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cacer:Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016;17(5):350-361. doi:10.1016/j.cllc.2016.03.011.; https://www.med-sovet.pro/jour/article/view/5036

الاتاحة: https://www.med-sovet.pro/jour/article/view/5036
https://doi.org/10.21518/2079-701X-2019-19-16-21

المؤلفون: K. Laktionov K., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., D. Marinov T., D. Peregudov A., M. Ardzinba S., К. Лактионов К., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П., Д. Маринов Т., Д. Перегудов А., М. Ардзинба С.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2019); 110-114 ; Медицинский Совет; № 10 (2019); 110-114 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-10

مصطلحات موضوعية: NSCLC, EGFR, tyrosine kinase inhibitors, integrated chemotherapy, НМРЛ, ингибиторы тирозинкиназы, интегрированная химиотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3060/2984; Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-246.; Sequist L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.; Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.; Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis. PLOS ONE. 2013 November 8;8(Issue 11):e79000. www.plosone.org; Kanda S., Horinouchi H., Fujiwara Y., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Kubota K., Tamura T., Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 2015 Sep;89(3):287-93.; Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;278(2):113-125.; Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932–20937.; Engleman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O. et al. MET amplification leads to gefitinib resistance in lung cancer by activation ERBB3 signaling. Science. 2007;316:1039–1043.; Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.; Soria J.C., Wu Y.L., Nakagawa K. et al. Gefi tinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-smallcell lung cancer after progression on first-line gefi tinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–98.; Saito H., Fukuhara T. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous nonsmall- cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35.; Nakamura A., Inoue A. et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Journal of Clinical Oncology. 2018 May 20;36(15_suppl):9005-9005.; https://www.med-sovet.pro/jour/article/view/3060

الاتاحة: https://www.med-sovet.pro/jour/article/view/3060
https://doi.org/10.21518/2079-701X-2019-10-110-114

المؤلفون: K. Laktionov K., V. Breder V., D. Yudin I., K. Sarantseva A., L. Laktionova V., M. Ardzinba S., E. Reutova V., A. Egorova V., К. Лактионов К., В. Бредер В., Д. Юдин И., К. Саранцева А., Л. Лактионова В., М. Ардзинба С., Е. Реутова В., А. Егорова В.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 22-29 ; Медицинский Совет; № 19 (2019); 22-29 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: neoadjuvant immunotherapy, non-small cell lung cancer, checkpoint inhibitors, неоадъювантная иммунотерапия, немелкоклеточный рак легкого, ингибиторы контрольных точек

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5047/4596; Eberhardt W.E., Mitchell A., Crowley J., Kondo H., Kim Y.T., Turrisi A. 3rd, Goldstraw P., RamiPorta R. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515-22. doi:10.1097/JTO.0000000000000673.; Asamura H., Chansky K., Crowley J., Goldstraw P., Rusch V.W., Vansteenkiste J., et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):1675–1684. doi:10.1097/JTO.0000000000000678.; Rami-Porta R., Bolejack V., Crowley J., Ball D., Kim J., Lyons G., et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):990–1003. doi:10.1097/JTO.0000000000000559.; Hilaris B.S., Gomez J., Nori D., Anderson L.L., Martini N. Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer. Cancer. 1985;(55):1226–1231. doi:10.1002/1097-0142(19850315)55:63.0.co;2-6.; Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G. 4th, Reddy S., Lee M.S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989;(47):669–675; discussion 676-667. doi:10.1016/0003-4975(89)90115-x.; Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Cantó A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;(330):153–158. doi:10.1056/NEJM199401203300301.; Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam J.B. Jr., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst. 1994;(86):673–680. doi:10.1093/jnci/86.9.673.; Pisters K.M., Vallieres E., Crowley J.J., Franklin W.A., Bunn P.A. Jr, Ginsberg R.J., Putnam J.B. Jr., Chansky K., Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in earlystage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;(28):1843–1849. doi:10.1200/JCO.2009.26.1685.; Felip E., Rosell R., Maestre J.A., RodríguezPaniagua J.M., Morán T., Astudillo J., Alonso G. et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-smallcell lung cancer. J Clin Oncol. 2010;(28):3138–3145. doi:10.1200/JCO.2009.27.6204.; Scagliotti G.V., Pastorino U., Vansteenkiste J.F., Spaggiari L., Facciolo F., Orlowski T.M., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–smallcell lung cancer. J Clin Oncol. 2012;(30):172–178. doi:10.1200/JCO.2010.33.7089.; Burdett S., Stewart L., Auperin A., Pignon J.P. Chemotherapy in non–small-cell lung cancer: an update of an individual patient data metaanalysis. J Clin Oncol. 2005; (23):924–925. author reply 925-926. doi:10.1200/JCO.2008.17.7162.; Garon E.B., Hellmann M.D., Costa E.C., et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019 (suppl; abstr LBA9015). doi:10.1200/JCO.2019.37.18_suppl.LBA9015.; Brahmer J., Borghaei H., Ramalingam S.S., Horn L., Holgado E., Pluzanski A., Burgioet M. et al. Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response. Conference: Proceedings: AACR Annual Meeting. 2019; March 29-April 3, 2019; Atlanta, GA. doi:10.1158/1538-7445.AM2019-CT195.; Horn L., Gettinger S., Gordon M., Herbst R., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer. 2018;(101):201-209. doi:10.1016/j.ejca.2018.06.031.; Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012.; Rusch V., Chaft J., Johnson B., Wistuba I., Kris M., Lee J. et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Journal of Clinical Oncology. 2018;36(15_suppl):8541-8541. doi:10.1200/JCO.2018.36.15_suppl.8541.; Cascone T., William W.N., Weissferdt A., Leung C.H., Federico L., Haymaker C. et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;(37S):ASCO#8504. doi:10.1200/JCO.2019.37.15_suppl.8504.; Forde P.M., Chaft J.E., Smith K.N., Anagnostou V., Cottrell T., Hellmann M., Zahurak M., Yang S. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-1986. doi:10.1056/NEJMoa1716078.; Chaft J.E., Rusch V., Ginsberg M.S., Paik P.K., Finley D.J., Kris M.G., et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013;8(8):1084-1090. doi:10.1097/JTO.0b013e31829923ec.; Provencio M., Nadal E., Insa A., García Campelo R., Huidobro G., Domine M. et al. WCLC 2018 Abstract OA01.05. Available at: https://adisinsight.springer.com/trials/700281155.; Shu C., Grigg C., Chiuzan C., Garofano R., Patel V., Hernandezet S. et al. Neoadjuvant atezolizumab + chemotherapy in resectable nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology. 2018;36(15_suppl):8532-8532. doi:10.1200/JCO.2018.36.15_suppl.8532.; https://www.med-sovet.pro/jour/article/view/5047

الاتاحة: https://www.med-sovet.pro/jour/article/view/5047
https://doi.org/10.21518/2079-701X-2019-19-22-29